Affimed price target lowered to $15 from $20 at Wells Fargo

Wells Fargo lowered the firm’s price target on Affimed (AFMD) to $15 from $20 and keeps an Overweight rating on the shares. The firm notes that r/r HL data for acimtamig plus allo NK from Cohorts 3 and 4 of the Phase 2 run-in portion are consistent with prior cohorts, with key opinion leaders feedback being positive. Wells also points out r/r AML monotherapy data as continuing to be promising.